Table 2

Paired sample t-test analyses showing the change in patient reported outcome measures (PROMs) and best corrected visual acuity (BCVA) measured during 12 months follow-up for all patients and for the subgroups where treatment included better seeing-eye and patients for which treatment only included the worse-seeing eye

All patients treated eyePatients with best seeing eye treatedPatients with worst seeing eye treated
B3 m6 m12 mB3 m6 m12 mB3 m6 m12 m
BCVA logMAR treated eye
Fractional
0.59
20/78
0.44**
20/55
0.38**
20/48
0.34**
20/44
0.39
20/49
0.33
20/43
0.28*
20/38
0.32
20/42
0.69
20/94
0.48**
20/60
0.42**
20/53
0.35**
20/45
NEI-VFQ-2579.782.2**82.6**82.1*71.076.9**76.4**76.1*83.084.284.984.4
PASS 53.32.8**2.7**2.8**3.62.9**2.9**3.0**3.22.8**2.6**2.7**
EQ-5D0.740.730.760.770.680.690.730.740.770.740.770.78
DITAMD managementNA8.38.47.9NA8.28.47.9NA8.38.47.9
  • Bold denotes significant change from baseline: **p < 0.001 and *p < 0.05.

  • B, baseline;DITAMD, Dimensions of Importance in Treatment of neovascular Age-related Macular Degeneration; EQ-5D, EuroQol Group Questionnaire; 6m, 6 months;12m, 12 months; 3 m, 3 months;NA, Not applicable; NEI-VFQ-25, National Eye Institute Visual-Functioning-Questionnaire-25.